|
Post by kc on Feb 6, 2018 14:25:02 GMT -5
Editorial contributor to the www.endocrine.org/ ENDO 2018 March 17-20, 2018 McCormick Place West Chicago, Illinois
Join us at ENDO 2018, the most well attended and valued translational endocrinology meeting in the world. Bringing together leading experts, researchers, and the most respected clinicians in the field, ENDO represents a convergence of science and practice that highlights and facilitates breakthrough discoveries in the field of endocrinology. Spend time connecting with peers and colleagues, exchanging ideas and information, and getting out in front of the latest trends and advancements in hormone health.
Key Dates: Late-Breaking Abstract Submission: January 11 – February 5, 2018
Maybe they STAT study will be released at ENDO 2018.
Probably too late to get a Booth at the event.
As an exhibitor at ENDO you will reach your prospects and gain recognition for your company’s products and services among 7,500+ endocrinologists. Here are some of the ways we build traffic and help companies exceed their exhibit expectations. The schedule contains 1 hour of completely unopposed time on all three days when the Expo is open
ENDO 2017 attendance totaled more than 7,500, including 5,900+ clinical endocrinologists, and 2,350 abstracts were presented Expo Theater Sessions were sold out, and averaged 150 attendees each – maximum capacity
Poster sessions are interspersed throughout the Expo Necessities like food stations, complimentary coffee, recharging stations, and more are all available in the Expo Science Hubs – Two locations will be located in the Expo Hall to host a wide variety of programs including the top scoring posters
Late-Breaking Submission Deadline: Monday, February 5, 2018, 1:00 PM EST
At ENDO 2018, you can expect leaders in endocrine practice and hormone research to share their latest breakthroughs that advance science and shape the future of patient care. By submitting your research for presentation at ENDO, you are not only helping to facilitate that exchange of information, you also gain valuable feedback from peers while fostering relationships for potential new partners.
By submitting your research for presentation at ENDO, you will not only have the chance to get your research in front of an engaged audience, but all accepted abstracts will also be published in Endocrine Reviews. Endocrine Reviews is ranked 4th of 138 journals in the category of Endocrinology & Metabolism with an impact factor of 15.745.
The media look to ENDO to discover the latest groundbreaking research and treatments. News articles highlighting ENDO 2017 reached nearly 2 billion unique visitors on online news sites and nearly 447,000 print readers. Stories about the meeting appeared in top-tier outlets, including The Wall Street Journal, Yahoo! Beauty, Reuters news wire service, Men’s Health magazine, International Business Times, Health magazine, London newspaper The Daily Telegraph, and STAT News, a health news site run by the owners of The Boston Globe
www.betacellsindiabetes.org/about/author?page=1 A resource for healthcare providers established by The Endocrine Society.
Our mission:
Engage primary care physicians in pathophysiology-based clinical decision making through an interactive educational format that stimulates debate and encourages physicians to incorporate the new science into their treatment regimens for patients with type 2 diabetes.
Background
In September, 2010, The Endocrine Society launched BetacellsinDiabetes.org based on recommendations from a meeting which brought together basic researchers, clinical endocrinologists, and primary care physicians (PCPs) to discuss the need to improve understanding of the role of beta cells as key drivers in the natural history of T2DM. The hope is that this effort will aid primary care physicians in the interpretation of concepts of disease pathogenesis, such as beta cell dysfunction, and improve medical decision-making in T2DM.
Funders
BetacellsinDiabetes.org is supported by an educational grant from Novo Nordisk, Inc and contributions from Lilly USA, LLC (for further information concerning Lilly grant funding (visit http://www.lillygrantoffice.com) and Merck & Co., Inc.
|
|
|
Post by kc on Feb 6, 2018 14:04:14 GMT -5
So maybe Lilly will acquire mnkd? They need a great Meal time insulin product. Then yes he knows the right people at Lilly to advance the case for a partnership.
|
|
|
Post by kc on Feb 6, 2018 14:02:08 GMT -5
IMO they bought his network. Mike is aiming to balance all his elements in the pipeline. He needed an important/expensive role to push Afrezza. There are barriers right now and I assume that he tries to get past them by improving acceptance and awareness. That is more needed than an operational guy running the pipeline in the role of a CMO. WINNER WINNER CHICKEN DINNER...........
VERY CREDIBLE HIRE WHO CAN PRESENT THE STAT STUDY AT ADA. WELL KNOWN ADA PRESENTER.
|
|
|
Post by kc on Feb 6, 2018 0:13:06 GMT -5
Lots of margin calls going on the past to trading sessions. I believe this probably will be good for mannkind long term. Shorty is having to pay up.
|
|
|
Post by kc on Feb 3, 2018 0:16:48 GMT -5
Hey, Pete and his brother are on Cramer talking about the market:-) Live in Minneapolis. Pete is good about responding on his Twitter feed. Like Nate he thought that AAPL was a good buy today. Off its high of 180.00 Couldn’t help myself. Had to buy at a discount today.
|
|
|
Post by kc on Jan 29, 2018 12:33:58 GMT -5
This would be a very helpful thing if they can treat Pulmonary Hypertension with a Technsphere size inhaler. Can you imagine how much easier life would be for a person with Pulmonary Hypertension.
|
|
|
Post by kc on Jan 29, 2018 10:45:50 GMT -5
Seems lack of real time access with lack of PR means nothing material coming out in the talk. Hey, DBC, there's that negativity again. Tell me then, why is the SP currently at $3.22? Ah, coming back down now - $3.11 Who's that Ken Cooper? KC, do you know him? Does anyone have access to him? We need a fly on the wall. Ken is a shareholder who I met two years ago at the Shareholders meeting. He and his wife attended it. Lives in Ft. Lauderdale.
|
|
|
Post by kc on Jan 29, 2018 10:44:50 GMT -5
He is from England. So probably not an Afrezza user.
|
|
|
Post by kc on Jan 29, 2018 10:16:04 GMT -5
There would never be a release of material events at a investment conference. That is not the way its done
|
|
|
Post by kc on Jan 29, 2018 10:08:37 GMT -5
Seems that we will get access 24 hours from now.
But we do have boots on the Ground Ken Cooper is at the Conference. Maybe he will record it.
|
|
|
Post by kc on Jan 28, 2018 22:53:07 GMT -5
Thank goodness it was not the bad kind of spam.
|
|
|
Post by kc on Jan 27, 2018 20:30:23 GMT -5
After owning MannKind shares for a decade, I have had to wrestle with the question of whether I am a fool, ignorant or dedicated to a great cause. On days like Thursday, I felt like I finally could say I know what I am doing. Followed by Friday, where I scolded myself for being an idiot. LOL. What a crazy two days. So, after many, many years of holding this stock, what do I believe? I BELIEVE: that Afrezza is a miracle treatment for diabetes. It so closely mimics a healthy pancreas that it provides a healthy path for a diabetic to gain incredible control of their sugars such that the liver and other organs operate properly. I BELIEVE: that Afrezza provides a clear path towards helping a diabetic (either Type 1 or 2) achieve A1c below 7. I BELIEVE: that Afrezza when teamed up with a CGM, will provide the real time control of a non-diabetic. So much so that a diabetic can live life between the lines with very little risk of hypoglycemia. I BELIEVE: that the current medical industry is stuck in a dangerous rut that puts diabetics at risk. By only focusing on A1c measures, which is only an average, the medical industry ignores the wild sugar swings that most diabetics endure. These swings cause long term damage to the eyes, the feet and other organs. By the time insulin is used, the damage has been done. I BELIEVE: that Afrezza will be at the heart of a major revolution for the treatment of diabetes across the world. Therefore: I WILL: hold on to my shares tightly and buy more shares when I can afford it. I WILL: not allow my shares to be borrowed for shorting. I WILL: be prepared at any time to share the Afrezza message with whoever will listen. I WILL: stand fast in the face of the many naysayers and whatever lies or deception they throw at me. MannKind and Afrezza will change the diabetic world. CentralCoastInvestor its because of people like you and Leanne and the other folks on this board, that keep me invested in MannKind. Yes its a strange society of Investor misfits but like the rest of us we have bought into the MannKind because of the potential of the product to be something very special if we can hang on long enough to see Afrezza become the gold stand for Diabetes treatment. I’m a savy businessman and have been fortunate over my life and career to be part of winners. My investment in MannKind represents one of the biggest losses that I have ever taken over my lifetime. Yes I took the losse in 2016 when I had a big capital gain elsewhere. That was the most painful event I have ever had. Yes it hurt for me to be out that much cash. But even more painful was being out of MannKind for 31 day in 2016. That was painful. I figured that would be the 31 day period that MannKind would explode. Fortunately its didn’t. So I bought back in at the end of 31 days. Now here I am waiting for that day we all win big or go home disappointed. I’m betting on winning big as Mike Castagna so far has excuted the restructuring and marketing plan correctly. I hope that we all one day can meet for a big celebration of the strange society of investor misfits.
|
|
|
Post by kc on Jan 26, 2018 21:48:35 GMT -5
So are we going to set up a go fund me page to buy the report?
|
|
|
Post by kc on Jan 26, 2018 21:38:32 GMT -5
Abbott in not in the drug business they are in the CGM and supply business. They would not be a buy in partner / perhaps They might pay MannKind to market to Dr’s their new freestyle
|
|
|
Post by kc on Jan 26, 2018 14:07:44 GMT -5
Only if you present it in a gold-pressed-latinum chalice. In that case, please fill said goblet with MNKDrano-wine. Drink slowly from this and don't take big gulps.....It is perfectly set up for the drano wine.
|
|